SEC Form 4 · accession 0001349929-17-000038
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Igor Gitelman
Officer — Chief Accounting Officer
Period of report
May 23, 2017
Accepted (ET)
May 25, 2017 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | May 23, 2017 | M | 937 | $2.50 | A | 937 | D | |
| Common Stock, par value $0.0001 per shareF1 | May 23, 2017 | S | 937 | $4.0164 | D | 0 | D | |
| Common Stock, par value $0.0001 per share | May 25, 2017 | P | 937 | $3.95 | A | 937 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.50 | May 23, 2017 | M | 937 | D | — | Feb 22, 2027 | Common Stock, par value $0.0001 per share | 937 | 14,063 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.025 to $4.01, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- F2The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period.